

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**PARRY, ROMANI, DECONCINI & SYMMS**

2. Address:

517 C STREET, NE, WASHINGTON, DC 20002

3. Principal place of business (if different from line 2):

Country: \_\_\_\_\_ City: \_\_\_\_\_ State/Zip(or Country): \_\_\_\_\_

4. Contact Name: MICHELLE MAGOON

Telephone: 202-547-4000

E-mail (optional): mmagoon@lobbycongress.com

Senate ID #: 30792-2206

House ID #: 30115147

7. Client Name:  Self

**NOVARTIS VACCINES AND DIAGNOSTICS, INC.**

### TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: \_\_\_\_\_ 11. No Lobbying Activity:

### INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

#### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): 40,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): \_\_\_\_\_

#### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

**Method A.** Reporting amounts using LDA definitions only

**Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

**Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: PARRY, ROMANI, DECONCINI & SYMMS Client Name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

**LOBBYING ACTIVITY**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

H.R. 3010: Making appropriations for the Departments of Labor, Health and Human Services, and Education, and Related Agencies for the fiscal year ending September 30, 2006, and for other purposes. Lobbied for sufficient funding of the CDC and NIH. Funds for domestic vaccine supply, Centers for Disease Control, National Institutes of Health and Vaccine Injury Compensation Fund.

17. House(s) of Congress and Federal agencies contacted:

Department of Health and Human Services  
National Institutes of Health  
Centers for Disease Control and Prevention  
US House of Representatives  
US Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD  
Covered Official Position (if applicable):  
Name: DECONCINI, DENNIS  
Covered Official Position (if applicable):  
Name: HADDOW, JOHN  
Covered Official Position (if applicable):  
Name: ROCK, JAMES  
Covered Official Position (if applicable):  
Name: ROMANI, ROMANO  
Covered Official Position (if applicable):  
Name: STROM, THADDEUS  
Covered Official Position (if applicable):  
Name: SYMMS, STEVE  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: PARRY, ROMANI, DECONCINI & SYMMS Client Name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

**LOBBYING ACTIVITY**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

H.R. 2795: To amend title 35, United States Code, relating to the procurement, enforcement, and validity of patents. Lobbied to protect intellectual property rights. H.R. 2791: To amend title 35, United States Code, with respect to patent fees, and for other purposes. Lobbied for reasonable patent fees and to protect intellectual property rights. H.R. 357, S. 167: To provide for the protection of intellectual property rights, and for other purposes. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. H.R. 2795: To amend title 35, United States Code, relating to the procurement, enforcement, and validity of patents. Lobbied to protect the Biopharmaceutical industry's intellectual property rights. S. 167: A bill to provide for the protection of intellectual property rights, and for other purposes. Lobbied to protect the Biopharmaceutical industry's intellectual property rights.

17. House(s) of Congress and Federal agencies contacted:

US House of Representatives

US Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD

Covered Official Position (if applicable):

Name: DECONCINI, DENNIS

Covered Official Position (if applicable):

Name: HADDOW, JOHN

Covered Official Position (if applicable):

Name: ROCK, JAMES

Covered Official Position (if applicable):

Name: ROMANI, ROMANO

Covered Official Position (if applicable):

Name: STROM, THADDEUS

Covered Official Position (if applicable):

Name: SYMMS, STEVE

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: PARRY, ROMANI, DECONCINI & SYMMS Client Name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

S.969,H.R.3369: A bill to amend the Public Health Service Act with respect to preparation for an influenza pandemic, including an avian influenza pandemic, and for other purposes. Lobbied for the interests of the vaccine industry.H.R.650: To establish reasonable legal reforms that will facilitate the manufacture of vital, life-saving vaccines, and for other purposes. Lobbied for the interests of the vaccine industry. H.R.1297: To amend the Public Health Service Act with respect to the National Vaccine Injury Compensation Program. Lobbied for the interests of the vaccine industry. H.R.840,S.399: A bill to amend the Federal Food, Drug and Cosmetic Act with respect to the sale of prescription drugs through the internet, and for other purposes. Lobbied to ensure that the internet would not be used to import counterfeit and defective medical products. H.R.1808,S.334: To amend the Federal Food, Drug, and Cosmetic Act to create a uniform certification standard for Internet pharmacies and to prohibit Internet pharmacies from engaging in certain advertising activities, to prohibit the use of certain bank instruments for purchases associated with illegal Internet pharmacies, and for other purposes. Lobbied to ensure that the internet would not be used to import counterfeit and defective medical products. S.1873: A bill to prepare and strengthen the biodefenses of the United States against deliberate, accidental, and natural outbreaks of illness, and for other purposes. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines. H.R.3052,S.1527: Vaccine Access and Supply Act, lobbied for provisions to strengthen the domestic vaccine industry. H.R.3970: Bioterror and Pandemic Preparedness Protection Act, lobbied in support of provisions to assure domestic pandemic preparedness. S.1821: Pandemic Preparedness and Response Act, lobbied in support of provisions to assure domestic pandemic preparedness. S.1828: Influenza Vaccine Security Act of 2005, lobbied in support of provisions to assure as strong domestic vaccine industry. S.1912: Global Network for Avian Influenza Surveillance Act, lobbied in support of domestic pandemic preparedness. S.375: Flu Protection Act of 2005, lobbied in support of domestic influenza provisions to stabilize production and supply. S.969: Attacking Viral Influenza Across Nations Act of 2005, lobbied in support of influenza provisions. General matters related to vaccine industry stability, pandemic preparedness, avian influenza.

17. House(s) of Congress and Federal agencies contacted:

Food and Drug Administration  
Department of Health and Human ServicesUS House of Representatives  
US Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD  
Covered Official Position (if applicable):  
Name: DECONCINI, DENNIS  
Covered Official Position (if applicable):  
Name: HADDOW, JOHN  
Covered Official Position (if applicable):  
Name: ROCK, JAMES  
Covered Official Position (if applicable):  
Name: ROMANI, ROMANO  
Covered Official Position (if applicable):  
Name: STROM, THADDEUS  
Covered Official Position (if applicable):  
Name: SYMMS, STEVE  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above.**None**

Registrant Name: PARRY, ROMANI, DECONCINI & SYMMS Client Name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HOM (one per page)

16. Specific lobbying issues:

S. 3: A bill to strengthen and protect America in the war on terror. Lobbied for incentives to manufacture biomedical counter measures.  
S. 975: A bill to provide incentives to increase research by private sector entities to develop medical counter measures to prevent, detect, identify, contain, and treat illnesses, including those associated with biological, chemical, nuclear, or radiological weapons attack or an infectious disease outbreak, and for pandemic preparedness provisions. S. 1873: A bill to prepare and strengthen the biodefenses of the United States against deliberate, accidental, and natural outbreaks of illness, and for other purposes. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines. H.R. 1815, S. 1042: National Defense Authorizations Act for Fiscal Year 2006. Lobbied for a vaccine liability and compensation program for Pandemic Vaccines. H.R. 2601: To authorize appropriations for the Department of State for Fiscal Years 2006 and 2007. Lobbied for sufficient funding for bioterrorist medical counter measures.

17. House(s) of Congress and Federal agencies contacted:

Department of Health and Human Services  
Centers for Disease Control and Prevention  
US House of Representatives  
US Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD  
Covered Official Position (if applicable):  
Name: DECONCINI, DENNIS  
Covered Official Position (if applicable):  
Name: HADDOW, JOHN  
Covered Official Position (if applicable):  
Name: ROCK, JAMES  
Covered Official Position (if applicable):  
Name: ROMANI, ROMANO  
Covered Official Position (if applicable):  
Name: STROM, THADDEUS  
Covered Official Position (if applicable):  
Name: SYMMS, STEVE  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: PARRY, ROMANI, DECONCINI & SYMMS Client Name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

**LOBBYING ACTIVITY**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

No activity this period.

17. House(s) of Congress and Federal agencies contacted: **None**

18. Name of each individual who acted as a lobbyist in this issue area:

- Name: BAXTER, EDWARD  
Covered Official Position (if applicable):
- Name: DECONCINI, DENNIS  
Covered Official Position (if applicable):
- Name: HADDOW, JOHN  
Covered Official Position (if applicable):
- Name: ROCK, JAMES  
Covered Official Position (if applicable):
- Name: ROMANI, ROMANO  
Covered Official Position (if applicable):
- Name: STROM, THADDEUS  
Covered Official Position (if applicable):
- Name: SYMMS, STEVE  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above: **None**

Registrant Name: PARRY, ROMANI, DECONCINI & SYMMS Client Name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

**LOBBYING ACTIVITY**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TAX (one per page)

16. Specific lobbying issues:

No activity this period.

17. House(s) of Congress and Federal agencies contacted: **None**

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAXTER, EDWARD

Covered Official Position (if applicable):

Name: DECONCINI, DENNIS

Covered Official Position (if applicable):

Name: HADDOW, JOHN

Covered Official Position (if applicable):

Name: ROCK, JAMES

Covered Official Position (if applicable):

Name: ROMANI, ROMANO

Covered Official Position (if applicable):

Name: STROM, THADDEUS

Covered Official Position (if applicable):

Name: SYMMS, STEVE

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above: **None**

Signature: ON FILE Date: Jul 28, 2006

Printed Name and Title: Romano Romani, President -